

If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of New Mexico may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSNM has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT® Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

## **Diagnostic Testing of Common Sexually Transmitted Infections**

**Policy Number:** CPCPLAB051

**Version 1.0**

**Approval Date:** 09/26/2025

**Plan Effective Date:** 01/03/2026

## Description

The Plan has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

## Reimbursement Information:

This policy is limited to testing for *C. trachomatis*, *N. gonorrhoeae*, *T. pallidum*, *T. vaginalis*, HSV, and HPV. The following conditions and/or tests are discussed in the corresponding policies:

- Human Immunodeficiency Virus – CPCPLAB065
- Hepatitis B and C – CPCPLAB015
- Pediatric Preventive Screening – CPCPLAB016
- Cervical Cancer Screening – CPCPLAB002
- Pathogen Panel Testing – CPCPLAB045

For STI screening in pregnant individuals, please see CPCPLAB014 Prenatal Screening (Nongenetic).

1. Antibody testing for syphilis infection **may be reimbursable** in the following situations:
  - a. For any asymptomatic person in a high-risk category (**See Notes 1 & 2**), once a year assessment using either a “standard” or “reverse” algorithm that includes initial and confirmatory tests for any initial positive test such as:
    - i. Treponemal Ig test **AND**
    - ii. Nontreponemal test;
  - b. For diagnosis of any person presenting with signs and/or symptoms of a syphilis infection\* (**See Note 3**);
  - c. Once every three months for HIV-positive men or men who have sex with men (MSM);
  - d. Treponemal Ig testing and nontreponemal testing (once prior to transplant) as a part of a pre-transplant assessment in both donors and recipients for an allogeneic hematopoietic stem cell transplantation (allo-HCT);
  - e. When a nontreponemal test is used as a test of cure (TOC) for a positive syphilis infection.
2. For asymptomatic individuals NOT belonging to a high-risk category (**See Notes 1 & 2**) antibody screening for syphilis **may be reimbursable** only in the following situations:
  - a. As part of newborn screening;
  - b. As part of follow-up in a victim of sexual assault;
  - c. For sexually active individuals less than 18 years of age (annually).

3. Polymerase chain reaction (PCR) and nucleic acid amplification testing (NAAT) for syphilis **is not reimbursable**.
4. Qualitative nucleic acid amplification tests (NAATs) for chlamydia **may be reimbursable** in the following situations:
  - a. Once a year assessment for any asymptomatic person in a high-risk category (**See Notes 1 & 4**);
  - b. For diagnosis of any person presenting with signs and/or symptoms of a chlamydial infection (**See Note 5**);
  - c. For diagnosis of any person with suspected lymphogranuloma venereum (LGV);
  - d. As test of cure of treatment at least three months after initial chlamydial diagnosis.
5. For asymptomatic individuals NOT belonging to a high-risk category (**See Note 1 & 4**), NAAT screening for chlamydia **may be reimbursable** only in the following situations:
  - a. As part of newborn screening;
  - b. As part of follow-up of victim of sexual assault;
  - c. For sexually active individuals less than 18 years of age (annually).
6. Serology testing for chlamydia or lymphogranuloma venereum (LGV) **is not reimbursable**.
7. Qualitative nucleic acid amplification tests (NAATs) for gonorrhea **may be reimbursable** in the following situations:
  - a. Once a year assessment for any asymptomatic person in a high-risk category (**See Note 1 & 4**);
  - b. For diagnosis of any person presenting with signs and/or symptoms of a gonorrheal infection (**See Note 6**);
  - c. As test of cure for treatment.
8. For an individual that does not respond to initial treatment, culture testing for *N. gonorrhoeae* to determine antimicrobial susceptibility **may be reimbursable**.
9. For asymptomatic individuals NOT belonging to a high-risk category (**See Note 1 & 4**), NAAT screening for gonorrhea **may be reimbursable** only in the following situations:
  - a. As part of newborn screening;
  - b. As part of follow-up of victim of sexual assault;
  - c. For sexually active individuals less than 18 years of age (annually).
10. Qualitative NAAT for *T. vaginalis* **may be reimbursable** in the following situations:
  - a. For symptomatic individuals (**See Note 7**);
  - b. Follow-up testing a minimum of three months after initial trichomoniasis diagnosis

- c. Annual screening for asymptomatic individuals belonging to a high-risk group (See **Note 8**)
  - d. Annual screening for asymptomatic individuals who have an HIV infection
  - e. As part of follow-up in a victim of sexual assault.
11. Rapid identification of *Trichomonas* by enzyme immunoassay **is not reimbursable**.
  12. For symptomatic individuals (**See Note 8**), testing for *Mycoplasma genitalium* using qualitative NAAT **may be reimbursable**.
  13. For asymptomatic individuals (**See Note 9**), screening for *M. genitalium* using NAAT **is not reimbursable**.
  14. When an individual meets the conditions described above, multitarget PCR testing (targets limited to *C. trachomatis*, *N. gonorrhoeae*, *T. vaginalis*, and *M. genitalium*) **may be reimbursable**.
  15. For individuals with active genital ulcers or mucocutaneous lesions, qualitative NAAT for herpes simplex virus (HSV-1) or herpes simplex virus-2 (HSV-2) **may be reimbursable**.
  16. Immunoassay testing for herpes simplex virus-1 (HSV-1), and/or herpes simplex (non-specific type test) **is not reimbursable**.
  17. Type-specific serologic testing for herpes simplex virus-2 (HSV-2) using a glycoprotein G2 (gG2) **may be reimbursable** in the following situations:
    - a. Recurrent or atypical genital symptoms or lesions in individuals with a negative herpes simplex virus PCR or culture result;
    - b. For the clinical diagnosis of genital herpes in individuals with a negative PCR or culture result or without laboratory confirmation;
    - c. When an individual's partner has genital herpes.
  18. Screening for herpes simplex virus-1 or herpes simplex virus-2 (HSV-1 and HSV-2) in asymptomatic individuals **is not reimbursable**.
  19. In the diagnosis and/or assessment of cancer or cancer therapy (immunohistochemistry testing for p16 or NAAT testing for high-risk human papillomavirus [HR-HPV]), testing for HR-HPV **may be reimbursable**.
  20. Testing for HPV **is not reimbursable** in the following situations:
    - a. To screen for oncogenic high-risk types, such as HPV-16 and HPV-18, as part of a general sexually transmitted disease (STD) or sexually transmitted infection (STI) screening process or panel for asymptomatic patients;
    - b. As part of diagnosis of anogenital warts;
    - c. Testing for low-risk types of HPV;

- d. In the general population either as part of a panel of tests or as an individual NAAT to determine HPV status.
21. Prior to beginning a Preexposure prophylaxis (PrEP) regimen, triple panel testing (hepatitis B surface antigen [HBsAg], hepatitis B surface antibody [anti-HBs], total antibody to hepatitis B core antigen [anti-HBc]) to screen for hepatitis B **may be reimbursable**:
22. Prior to beginning or while an individual is undergoing a preexposure prophylaxis (PrEP) regimen for HIV prevention, the following screens/tests for additional STIs **may be reimbursable**:
  - a. Qualitative NAAT screening for gonorrhea and chlamydia:
    - i. Once every three months for MSM
    - ii. Once every six months for sexually active individuals
  - b. Blood test to screen for syphilis:
    - i. Once every three months for MSM
    - ii. Once every six months for sexually active individuals.
23. Nucleic acid testing to determine antimicrobial susceptibility in *N. gonorrhoeae* or macrolide resistance in *M. genitalium* **is not reimbursable**.
24. Direct probe detection and/or quantitative NAAT for the following microorganisms **is not reimbursable**:
  - a. *Chlamydia trachomatis*
  - b. *Neisseria gonorrhoeae*
  - c. Herpes Simplex Virus-1
  - d. Herpes Simplex Virus-2
  - e. Human Papillomavirus
  - f. *Treponema pallidum*

**NOTE 1:** For sexually active children and adolescents under the age of 18, risk factors for chlamydia, gonorrhea and/or syphilis infection as defined by the CDC include: (4)

- Initiating sex early in adolescence;
- Living in detention facilities;
- Receiving services at STD clinics;
- Being involved in commercial sex exploitation or exchanging sex for drugs, money, food, or housing;
- Having multiple sex partners;
- Having sequential sex partners of limited duration or concurrent partnerships;
- Failing to use barrier protection consistently and correctly;
- Having lower socioeconomic status, and facing numerous obstacles to accessing healthcare;
- At risk individuals also include:
  - Males who have sex with males (YMSM);
  - Transgender youths;

- Youths with disabilities, substance abuse, or mental health disorders.

**NOTE 2: High-risk for Syphilis (5,6):**

- Sexually active men who have sex with men (MSM);
- Sexually active individuals with an HIV-positive status;
- Having a sexual partner recently diagnosed with an STI;
- Exchanging sex for money or drugs;
- Individuals in adult correctional facilities;
- During pregnancy when the following risk factors are present:
  - Sexually active HIV-positive status;
  - Sexually active with multiple partners;
  - Sexually active in conjunction with drug use or transactional sex;
  - Late-entry to prenatal care (i.e., first visit during the second trimester or later) or no prenatal care;
  - Methamphetamine or heroin use;
  - Incarceration of the woman or her partner;
  - Unstable housing or homelessness.

**NOTE 3: Signs and Symptoms of a Syphilis Infection (5,7)**

- Chancre;
- Skin rash and/or mucous membrane lesions in mouth, vagina, anus, hands, and feet;
- Condyloma lata;
- Secondary symptomology can include fever, fatigue, sore throat, swollen lymph nodes, weight loss, muscle aches, headache, and hair loss;
- Signs and symptoms of neurosyphilis can include severe headache, trouble with muscle movements, muscle weakness or paralysis (not being able to move certain parts of the body), numbness, and changes in mental status (trouble focusing, confusion, personality change) and/or dementia (problems with memory, thinking, and/or making decisions).
- Signs and symptoms of ocular syphilis can include eye pain or redness, floating spots in the field of vision (“floaters”), sensitivity to light, and changes in vision (blurry vision or even blindness).
- Signs and symptoms of otosyphilis may include hearing loss, ringing, buzzing, roaring, or hissing in the ears (“tinnitus”), balance difficulties, and dizziness or vertigo.
- Signs and symptoms of late/tertiary syphilis include inflammatory lesions of the cardiovascular system (e.g., aortitis, coronary vessel disease), skin (e.g., gummatous lesions), and bone (e.g., osteitis).

**NOTE 4: High-risk for Chlamydia and/or Gonorrhea (8-11):**

- Sexually active men who have sex with men (MSM);
- Sexually active individuals with an HIV-positive status;
- Sexually active individuals with a cervix who are under the age of 25;
- Individuals with a cervix who are 25 years of age or older and who have multiple sexual partners, multiple sexual partners, or a sex partner with concurrent partners; practice inconsistent condom use when not in a mutually monogamous relationship;

- Having a sexual partner recently diagnosed with an STI;
- Previous or concurrent STI;
- Exchanging sex for money or drugs;

**NOTE 5: Signs and Symptoms of a Chlamydia Infection (8,11):**

- Genital symptoms, including “discharge, burning during urination, unusual sores, or rash;”
- Pelvic Inflammatory Disease, including “symptoms of abdominal and/or pelvic pain, along with signs of cervical motion tenderness, and uterine or adnexal tenderness on examination;”
- Urethritis;
- Pyuria;
- Dysuria;
- Increase in frequency in urination;
- Epididymitis (with or without symptomatic urethritis) in men;
- Proctitis;
- Sexually acquired chlamydial conjunctivitis.

**NOTE 6: Signs and Symptoms of Gonorrhea (10):**

- Dysuria;
- Urethral infection;
- Urethral or vaginal discharge;
- Epididymitis (Testicular or scrotal pain);
- Rectal infection symptoms include anal itching, discharge, rectal bleeding, and painful bowel movements.

**NOTE 7: Signs and Symptoms of Trichomoniasis (12):**

- Vaginal or penile discharge;
- Itching, irritation, burning sensation, or soreness of the genitalia;
- Discomfort or burning sensation during/after urination and/or ejaculation;
- Urethritis;
- Epididymitis;
- Prostatitis.

**Note 8: High-risk for Trichomoniasis: (13)**

- Receiving care in high-prevalence settings (e.g., STI clinics, correctional facilities)
- Having multiple sexual partners
- Exchanging sex for money or drugs
- Having a previous or concurrent STI
- Drug misuse
- History of incarceration
- Sexually active individuals with an HIV-positive status

**NOTE 9: Signs and Symptoms of *M. genitalium* Infection (14):**

- When present, typical symptoms of *M.gen*-urethritis in men include dysuria, urethral pruritus, and purulent or mucopurulent urethral discharge.

- When present, typical symptoms of *M.gen* cervicitis in women include vaginal discharge, vaginal itching, dysuria, and pelvic discomfort.
- When present, typical symptoms of PID due to *M.gen* include mild to severe pelvic pain, abdominal pain, abnormal vaginal discharge, and/or bleeding.

## Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Codes
86592, 86593, 86631, 86632, 86694, 86695, 86696, 86704, 86706, 86780, 87081, 87110, 87181, 87340, 87490, 87491, 87492, 87528, 87529, 87530, 87563, 87590, 87591, 87592, 87623, 87624, 87625, 87626, 87661, 87797, 87798, 87799, 87800, 87808, 88341, 88342, 88344, 0064U, 0065U, 0096U, 0210U, 0402U, 0455U, 0463U, 0483U, 0484U, G0499,

## References:

1. Ghanem KG, Tuddenham S. Screening for sexually transmitted infections. Updated May 13, 2025. <https://www.uptodate.com/contents/screening-for-sexually-transmitted-infections>
2. Palefsky JM. Human papillomavirus infections: Epidemiology and disease associations. Updated February 25, 2025. <https://www.uptodate.com/contents/human-papillomavirus-infections-epidemiology-and-disease-associations>
3. Albrecht MA. Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection. Updated October 28, 2024. <https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-infection>
4. CDC. Sexually Transmitted Infections Treatment Guidelines, 2021 - Adolescents. Updated July 22, 2021. <https://www.cdc.gov/std/treatment-guidelines/adolescents.htm>
5. CDC. About Syphilis. Updated January 30, 2025. <https://www.cdc.gov/syphilis/about/index.html>
6. Cantor AG, Pappas M, Daeges M, Nelson HD. Screening for syphilis: Updated evidence report and systematic review for the us preventive services task force. *JAMA*. 2016;315(21):2328-2337. doi:10.1001/jama.2016.4114
7. CDC. Syphilis (*Treponema pallidum*): 2018 Case Definition. Updated August 16, 2021. <https://ndc.services.cdc.gov/case-definitions/syphilis-2018/>
8. CDC. About Chlamydia. Updated January 31, 2025. <https://www.cdc.gov/chlamydia/about/index.html>
9. LeFevre ML. Screening for Chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. *Annals of internal medicine*. Dec 16 2014;161(12):902-10. doi:10.7326/m14-1981



10. CDC. About Gonorrhea. Updated January 31, 2025.  
<https://www.cdc.gov/gonorrhea/about/index.html>
11. CDC. Sexually Transmitted Infections Treatment Guidelines, 2021. Updated July 23, 2021. <https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf>
12. CDC. About Trichomoniasis. Updated January 31, 2025.  
<https://www.cdc.gov/trichomoniasis/about/index.html>
13. CDC. Screening Recommendations and Considerations Referenced in Treatment Guidelines and Original Sources. Updated March 22, 2024.  
<https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm>
14. CDC. Mycoplasma genitalium. Updated July 22, 2021.  
<https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm>
15. Hsu K. Clinical manifestations and diagnosis of Chlamydia trachomatis infections in adults and adolescents. Updated May 1, 2024.  
<https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chlamydia-trachomatis-infections-in-adults-and-adolescents>
16. CDC. Table 28. Chlamydia — Reported Cases and Rates of Reported Cases by State, Ranked by Rates, United States, 2023. Updated November 12, 2024.  
<https://www.cdc.gov/sti-statistics/data-vis/table-ct-state-ranked.html>
17. Goldstein E, Martínez-García L, Obermeier M, et al. Simultaneous identification of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas vaginalis—multicenter evaluation of the Alinity m STI assay. *Journal of Laboratory Medicine*. 2021;45(4-5):213-223. doi:10.1515/labmed-2020-0136
18. Ghanem KG. Clinical manifestations and diagnosis of Neisseria gonorrhoeae infection in adults and adolescents. Updated July 8, 2024.  
<https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-neisseria-gonorrhoeae-infection-in-adults-and-adolescents>
19. Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. *International journal of STD & AIDS*. Oct 29 2020;956462420949126. doi:10.1177/0956462420949126
20. CDC. The State of STIs - Infographic & Graphics. Updated April 3, 2024.  
<https://www.cdc.gov/sti/php/communication-resources/the-state-of-stis.html>
21. Hicks CB, Clement M. Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV. Updated December 20, 2023.  
<https://www.uptodate.com/contents/syphilis-epidemiology-pathophysiology-and-clinical-manifestations-in-patients-without-hiv>
22. Hicks CB, Clement M. Syphilis: Screening and diagnostic testing. Updated August 21, 2024. <https://www.uptodate.com/contents/syphilis-screening-and-diagnostic-testing>
23. Janier M, Hegyi V, Dupin N, et al. 2014 European guideline on the management of syphilis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Dec 2014;28(12):1581-93. doi:10.1111/jdv.12734
24. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports*. Jun 5 2015;64(Rr-03):1-137.
25. CDC. About Genital Herpes. Updated February 20, 2024.  
<https://www.cdc.gov/herpes/about/index.html>

26. Riley LE, Wald A. Genital herpes simplex virus infection and pregnancy. Updated October 17, 2024. <https://www.uptodate.com/contents/genital-herpes-simplex-virus-infection-and-pregnancy>
27. CDC. About Genital HPV Infection. Updated January 31, 2025. <https://www.cdc.gov/sti/about/about-genital-hpv-infection.html>
28. Feldman S, Crum CP. Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing. Updated June 24, 2025. <https://www.uptodate.com/contents/cervical-cancer-screening-tests-techniques-for-cervical-cytology-and-human-papillomavirus-testing>
29. USPSTF. Genital Herpes Infection: Serologic Screening. Updated February 14, 2023. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/genital-herpes-serologic-screening>
30. USPSTF. Prevention of Acquisition of HIV: Preexposure Prophylaxis. Updated August 22, 2023. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis#citation47>
31. WHO. Global HIV & AIDS statistics — Fact sheet. <https://www.unaids.org/en/resources/fact-sheet>
32. CDC. Clinical Guidance for PrEP. Updated February 10, 2025. <https://www.cdc.gov/hivnexus/hcp/prep/index.html>
33. BD. BD receives FDA Approval for HPV Test with Extended Genotyping Capabilities. <https://www.bd.com/en-us/company/news-and-media/press-releases/july-22-2020-bd-receives-fda-approval-for-hpv-test-with-extended-genotyping-capabilities>
34. FDA. BD ONCLARITY HPV ASSAY. <https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=391601>
35. FDA. 501(k) Premarket Notification Xpert CT/NG. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K121710>
36. FDA. 501(k) Premarket Notification Xpert CT/NG, GeneXpert Dx System, GeneXpert Infinity-48s and GeneXpert Infinity-80 Systems, GeneXpert Infinity-48 System, Xpert Vaginal/Endocervical Specimen Collection, Xpert Urine Specimen Collection Kit, Xpert Swab Specimen Collection Kit. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K190441>
37. FDA. 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY K121710. [https://www.accessdata.fda.gov/cdrh\\_docs/reviews/K121710.pdf](https://www.accessdata.fda.gov/cdrh_docs/reviews/K121710.pdf)
38. FDA. 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY K190441. [https://www.accessdata.fda.gov/cdrh\\_docs/reviews/K190441.pdf](https://www.accessdata.fda.gov/cdrh_docs/reviews/K190441.pdf)
39. Cepheid. Xpert® CT/NG. <https://www.cepheid.com/Package%20Insert%20Files/Xpert-CTNG-US-ENGLISH-Package-Insert-301-0234--Rev-K.pdf>
40. Abbott. Alinity m STI AMP Kit. <https://www.molecularcatalog.abbott/int/en/alinity-m-sti-assay>

41. Cook RL, Hutchison SL, Ostergaard L, Braithwaite RS, Ness RB. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. *Annals of internal medicine*. Jun 7 2005;142(11):914-25. doi:10.7326/0003-4819-142-11-200506070-00010
42. Golden M, O'Donnell M, Lukehart S, et al. Treponema pallidum Nucleic Acid Amplification Testing To Augment Syphilis Screening among Men Who Have Sex with Men. *J Clin Microbiol*. Aug 2019;57(8)doi:10.1128/jcm.00572-19
43. Wong EH, Klausner JD, Caguin-Grygiel G, et al. Evaluation of an IgM/IgG sensitive enzyme immunoassay and the utility of index values for the screening of syphilis infection in a high-risk population. *Sexually transmitted diseases*. Jun 2011;38(6):528-32. doi:10.1097/OLQ.0b013e318205491a
44. Tsang RS, Martin IE, Lau A, Sawatzky P. Serological diagnosis of syphilis: comparison of the Trep-Chek IgG enzyme immunoassay with other screening and confirmatory tests. *FEMS immunology and medical microbiology*. Oct 2007;51(1):118-24. doi:10.1111/j.1574-695X.2007.00289.x
45. Juarez-Figueroa L, Uribe-Salas F, Garcia-Cisneros S, Olamendi-Portugal M, Conde-Glez CJ. Evaluation of a rapid strip and a particle agglutination tests for syphilis diagnosis. *Diagnostic microbiology and infectious disease*. Oct 2007;59(2):123-6. doi:10.1016/j.diagmicrobio.2007.04.008
46. Feltner C, Grodensky C, Ebel C, et al. Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. Dec 20 2016;316(23):2531-2543. doi:10.1001/jama.2016.17138
47. Glass N, Nelson, Heidi D. Screening for Genital Herpes Simplex: A Brief Update for the U.S. Preventive Services Task Force. Updated December 20, 2023. <https://www.uspreventiveservicestaskforce.org/Home/GetFile/1/733/herpesup/pdf>
48. Castle PE, Stoler MH, Wright TC, Jr., Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. *The Lancet Oncology*. Sep 2011;12(9):880-90. doi:10.1016/s1470-2045(11)70188-7
49. Guenat D, Launay S, Riethmuller D, Mouglin C, Pretet JL. Validation of Novaprep((R)) HQ+ liquid-based cytology medium for high-risk human papillomavirus detection by hc2. *Infectious agents and cancer*. 2016;11:41. doi:10.1186/s13027-016-0092-7
50. Tshomo U, Franceschi S, Tshokey T, et al. Evaluation of the performance of Human Papillomavirus testing in paired urine and clinician-collected cervical samples among women aged over 30 years in Bhutan. *Virology journal*. Apr 8 2017;14(1):74. doi:10.1186/s12985-017-0744-2
51. Pham MD, Wise A, Garcia ML, et al. Improving the coverage and accuracy of syphilis testing: The development of a novel rapid, point-of-care test for confirmatory testing of active syphilis infection and its early evaluation in China and South Africa. *EClinicalMedicine*. Jul 2020;24:100440. doi:10.1016/j.eclinm.2020.100440
52. Bristow CC, Morris SR, Little SJ, Mehta SR, Klausner JD. Meta-analysis of the Cepheid Xpert(®) CT/NG assay for extragenital detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections. *Sex Health*. Aug 2019;16(4):314-319. doi:10.1071/sh18079

53. Cosentino LA, Danby CS, Rabe LK, et al. Use of Nucleic Acid Amplification Testing for Diagnosis of Extragenital Sexually Transmitted Infections. *J Clin Microbiol*. Sep 2017;55(9):2801-2807. doi:10.1128/jcm.00616-17
54. Kelly H, Coltart CEM, Pant Pai N, et al. Systematic reviews of point-of-care tests for the diagnosis of urogenital Chlamydia trachomatis infections. *Sexually transmitted infections*. Dec 2017;93(S4):S22-s30. doi:10.1136/sextrans-2016-053067
55. Guy RJ, Causer LM, Klausner JD, et al. Performance and operational characteristics of point-of-care tests for the diagnosis of urogenital gonococcal infections. *Sexually transmitted infections*. Dec 2017;93(S4):S16-s21. doi:10.1136/sextrans-2017-053192
56. Brischetto A, Gassiep I, Whiley D, Norton R. Retrospective Review of Treponema pallidum PCR and Serology Results: Are Both Tests Necessary? *J Clin Microbiol*. May 2018;56(5)doi:10.1128/jcm.01782-17
57. Zhiyan L, Meiling W, Ping L, Jinhua D, Zhenlin Y, Zhenru F. Consistency Between Treponema pallidum Particle Agglutination Assay and Architect Chemiluminescent Microparticle Immunoassay and Characterization of Inconsistent Samples. *Journal of clinical laboratory analysis*. Jul 2015;29(4):281-4. doi:10.1002/jcla.21765
58. Liu TY, Xie R, Luo L, et al. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples. *Journal of virological methods*. Feb 2014;196:120-5. doi:10.1016/j.jviromet.2013.10.032
59. Yao YL, Tian QF, Cheng B, Cheng YF, Ye J, Lu WG. Human papillomavirus (HPV) E6/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women. *Journal of Zhejiang University Science B*. Mar. 2017;18(3):256-262. doi:10.1631/jzus.B1600288
60. Arbyn M, Roelens J, Simoens C, et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. *The Cochrane database of systematic reviews*. Mar 28 2013;(3):Cd008054. doi:10.1002/14651858.CD008054.pub2
61. Gaydos CA, Ako MC, Lewis M, Hsieh YH, Rothman RE, Dugas AF. Use of a Rapid Diagnostic for Chlamydia trachomatis and Neisseria gonorrhoeae for Women in the Emergency Department Can Improve Clinical Management: Report of a Randomized Clinical Trial. *Ann Emerg Med*. Jul 2019;74(1):36-44. doi:10.1016/j.annemergmed.2018.09.012
62. NCCN. NCCN Clinical Practice Guidelines in Oncology Anal Carcinoma. Updated May 30, 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/anal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf)
63. Marcell AV, Health MTCfFPaR. Preventive Male Sexual and Reproductive Health Care: Recommendations for Clinical Practice. <https://californiaptc.com/wp-content/uploads/2019/12/Preventative-Male-Sexual-and-Reproductive-Health-Care.pdf>
64. NCCN. NCCN Clinical Practice Guidelines in Oncology Cervical Cancer. Updated March 24, 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/cervical.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf)
65. NCCN. NCCN Clinical Practice Guidelines in Oncology Head and Neck Cancers Updated August 12, 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf)

66. NCCN. NCCN Clinical Practice Guidelines Occult Primary (Cancer of Unknown Primary [CUP]). Updated September 11, 2024.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/occult.pdf](https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf)
67. NCCN. NCCN Clinical Practice Guidelines in Oncology Penile Cancer Updated January 6, 2025.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/penile.pdf](https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf)
68. NCCN. NCCN Clinical Practice Guidelines in Oncology Vulvar Cancer (Squamous Cell Carcinoma). Updated February 10, 2025.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/vulvar.pdf](https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf)
69. USPSTF. Chlamydia and Gonorrhea: Screening. Updated September 14, 2021.  
<https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/chlamydia-and-gonorrhea-screening>
70. Moyer VA. Screening for oral cancer: U.S. preventive services task force recommendation statement. *Annals of internal medicine*. 2014;160(1):55-60. doi:10.7326/M13-2568
71. Force UPST. Screening for Syphilis Infection in Nonpregnant Adolescents and Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement. *JAMA*. 2022;328(12):1243-1249. doi:10.1001/jama.2022.15322
72. Force UPST. Screening for Syphilis Infection During Pregnancy: US Preventive Services Task Force Reaffirmation Recommendation Statement. *JAMA*. 2025;333(22):2006-2012. doi:10.1001/jama.2025.5009
73. CDC. Clinical Guidance for STIs. Updated July 18, 2025.  
<https://www.cdc.gov/sti/hcp/clinical-guidance/index.html>
74. Papp JR PI, Fakile Y, Pereira L, Pillay A, Bolan GA. CDC Laboratory Recommendations for Syphilis Testing. *CDC MMWR Recomm Rep* 2024. 2024;73(No. RR-1):1–32doi:10.15585/mmwr.rr7301a1
75. CDC. Neurosyphilis, Ocular Syphilis, and Ootosyphilis. Updated March 7, 2024.  
<https://www.cdc.gov/syphilis/hcp/neurosyphilis-ocular-syphilis-otosyphilis/>
76. Dykewicz CA, Jaffe HW, Kaplan JE. Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients.  
<https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm>
77. CDC. Drug-Resistant Gonorrhea. Updated February 15, 2024.  
<https://www.cdc.gov/gonorrhea/hcp/drug-resistant/index.html>
78. CDC. Gonococcal Isolate Surveillance Project (GISP) Profiles. Updated April 15, 2025. <https://www.cdc.gov/sti-statistics/gisp-profiles/index.html>
79. Papp JR, Schachter J, Gaydos CA, Van Der Pol B. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. *MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports*. Mar 14 2014;63(Rr-02):1-19.
80. CDC. HPV & Men Fact Sheet. Updated April 18, 2022.  
[https://www.ihs.gov/sites/nptc/themes/responsive2017/display\\_objects/documents/sti\\_community/CDC-%20STD%20Facts%20-%20HPV%20and%20Men.pdf](https://www.ihs.gov/sites/nptc/themes/responsive2017/display_objects/documents/sti_community/CDC-%20STD%20Facts%20-%20HPV%20and%20Men.pdf)
81. CDC. Trichomoniasis. Updated September 21, 2022.  
<https://www.cdc.gov/std/treatment-guidelines/trichomoniasis.htm>
82. CDC. Sexual Assault and Abuse and STIs – Adolescents and Adults. Updated July 22, 2021. <https://www.cdc.gov/std/treatment-guidelines/sexual-assault-adults.htm>



83. Gilson R, Nugent D, Werner RN, Ballesteros J, Ross J. 2019 IUSTI-Europe guideline for the management of anogenital warts. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Aug 2020;34(8):1644-1653. doi:10.1111/jdv.16522
84. de Vries HJC, de Barbeyrac B, de Vrieze NHN, et al. 2019 European guideline on the management of lymphogranuloma venereum. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Oct 2019;33(10):1821-1828. doi:10.1111/jdv.15729
85. Janier M, Unemo M, Dupin N, Tiplica GS, Potocnik M, Patel R. 2020 European guideline on the management of syphilis. *Acta Clin Belg*. Jun 6 2020;doi:10.1080/17843286.2020.1773112
86. Lanjouw E, Ouburg S, de Vries HJ, Stary A, Radcliffe K, Unemo M. 2015 European guideline on the management of Chlamydia trachomatis infections. *International journal of STD & AIDS*. Apr 2016;27(5):333-48. doi:10.1177/0956462415618837
87. Patel R, Kennedy OJ, Clarke E, et al. 2017 European guidelines for the management of genital herpes. *International journal of STD & AIDS*. Dec 2017;28(14):1366-1379. doi:10.1177/0956462417727194
88. Public Health Agency of Canada. Anogenital warts guide: Key information and resources. Public Health Agency of Canada. Updated February 20 2025. <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/anogenital-warts.html>
89. Public Health Agency of Canada. Chlamydia and LGV guide: Key information and resources. Updated February 20 2025. <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/chlamydia-lgv.html>
90. Public Health Agency of Canada. Genital herpes guide: Key information and resources. Updated December 12, 2021. <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/herpes-simplex-virus.html>
91. Public Health Agency of Canada. Gonorrhea guide: Key information and resources. Updated December 23, 2024. <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/gonorrhea.html>
92. Public Health Agency of Canada. Mycoplasma Genitalium guide: Key information and resources. Updated December 22, 2021. <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/mycoplasma-genitalium.html>
93. Public Health Agency of Canada. Syphilis guide: Key information and resources. Updated April 15, 2025. <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/syphilis.html>
94. Murray P, Braverman P, Adelman W, et al. Screening for nonviral sexually transmitted infections in adolescents and young adults. *Pediatrics*. Jul 2014;134(1):e302-11. doi:10.1542/peds.2014-1024
95. NICE. National Institute for Health and Care Excellence: Clinical Guidelines. *Cancer of the Upper Aerodigestive Tract: Assessment and Management in People*

- Aged 16 and Over*. National Institute for Health and Care Excellence (UK) Copyright (c) National Collaborating Centre for Cancer.; 2018.
96. NICE. Reducing sexually transmitted infections. Updated June 15, 2022. <https://www.nice.org.uk/guidance/ng221>
  97. Society CP. Diagnosis and management of congenital syphilis – Avoiding missed opportunities. Updated March 28, 2024. <https://www.cps.ca/en/documents/position/congenital-syphilis>
  98. Canadian Paediatric Society. Comprehensive sexual health assessments for adolescents. Updated December 7, 2020. <https://cps.ca/en/documents/position/comprehensive-sexual-health-assessments-for-adolescents>
  99. White J, O'Farrell N, Daniels D. 2013 UK National Guideline for the management of lymphogranuloma venereum: Clinical Effectiveness Group of the British Association for Sexual Health and HIV (CEG/BASHH) Guideline development group. *International journal of STD & AIDS*. Aug 2013;24(8):593-601. doi:10.1177/0956462413482811
  100. Patel R, Green J, Clarke E, et al. 2014 UK national guideline for the management of anogenital herpes. *International journal of STD & AIDS*. Oct 2015;26(11):763-76. doi:10.1177/0956462415580512
  101. Nwokolo NC, Dragovic B, Patel S, Tong CY, Barker G, Radcliffe K. 2015 UK national guideline for the management of infection with Chlamydia trachomatis. *International journal of STD & AIDS*. Mar 2016;27(4):251-67. doi:10.1177/0956462415615443
  102. BASHH. Update on the treatment of Chlamydia trachomatis (CT) infection. [https://www.bashh.org/\\_userfiles/pages/files/resources/updateonthetreatmentofchlamydiatrachomatisinfectionfinal16918.pdf](https://www.bashh.org/_userfiles/pages/files/resources/updateonthetreatmentofchlamydiatrachomatisinfectionfinal16918.pdf)
  103. Kingston M, French P, Higgins S, et al. UK national guidelines on the management of syphilis 2015. *International journal of STD & AIDS*. May 2016;27(6):421-46. doi:10.1177/0956462415624059
  104. Ullmann AJ, Schmidt-Hieber M, Bertz H, et al. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. *Ann Hematol*. Sep 2016;95(9):1435-55. doi:10.1007/s00277-016-2711-1

## Policy Update History:

Approval Date	Effective Date; Summary of Changes
09/26/2025	01/03/2026 Document updated with literature review. The following changes were made to Reimbursement Information: For clarity added "qualitative" to "qualitative NAAT" in #4, #7, #12, #15; added "NAAT" to #5 and #9; revised #10 to state "Qualitative NAAT for T. vaginalis may be reimbursable in the following situations: a) For symptomatic individuals (see Note 5); b) Follow-up testing a minimum of three months after initial trichomoniasis diagnosis; c) Annual screening for asymptomatic individuals belong to a high-risk group (see Note 6); d) Annual screening for asymptomatic individuals who

	<p>have an HIV infection; e) As part of follow-up in a victim of sexual assault.” Revised #21 to state: “Prior to beginning a Preexposure prophylaxis (PrEP) regimen, triple panel testing (hepatitis B surface antigen [HBsAg], hepatitis B surface antibody [anti-HBs], total antibody to hepatitis B core antigen [anti-HBc]) to screen for hepatitis B may be reimbursable.” Revised #22 to state: “Prior to beginning or while an individual is undergoing a preexposure prophylaxis (PrEP) regimen for HIV prevention, the following screens/tests for additional STIs may be reimbursable: a) Qualitative NAAT screening for gonorrhea and chlamydia: i) Once every three months for MSM. ii) Once every six months for sexually active individuals. b) Blood testing to screen for syphilis: i) Once every three months for MSM. ii) Once every six months for sexually active individuals.” Revised leading statement in #24 to state: “Direct probe detection and/or quantitative NAAT”. Added codes 87626, 87800; removed codes 82565, 82575, 84702, 84703, 86701, 86702, 86703, 86705, 86803, 86804, 87660, 0500T, G0432, G0433, G0435, G0472, G0475, S3645. References revised.</p>
10/30/2024	<p>01/15/2025; Document updated with literature review. The following changes were made to Reimbursement Information: Added 1.d. Treponemal Ig testing and nontreponemal testing (once prior to transplant) as a part of a pre-transplant assessment in both donors and recipients for an allogeneic hematopoietic stem cell transplantation (allo-HCT); added 12: For symptomatic individuals (See Note 8), testing for Mycoplasma genitalium using NAAT may be reimbursable; added 13. For asymptomatic individuals (See Note 8), screening for M. genitalium using NAAT is not reimbursable; added T. vaginalis, and M genitalium to #13; added Nucleic acid testing to determine antimicrobial susceptibility in N. gonorrhoeae or macrolide resistance in M. genitalium is not reimbursable. Added additional signs and symptoms of a syphilis infection to Note 3; added Note 8 for Signs and Symptoms of M. genitalium infection. Added codes 87563, 0402U, 0455U, 0463U, 0483U, 0484U; removed 0167U, 0353U, 0354U. References revised.</p>
11/01/2023	<p>11/01/2023: Document updated with literature review. Reimbursement information revised for clarity. Added #10: When an individual meets the conditions described above for both chlamydia and gonorrhea, multitarget PCR testing (targets limited to C. trachomatis and N. gonorrhoeae) may be reimbursable. References revised; some added, others removed.</p>
11/1/2022	<p>11/01/2022: New policy</p>